智通财经APP获悉，复宏汉霖(02696)午后涨近10%，截至发稿，涨8.65%，报28.25港元，成交额1544.92万港元。
消息面上，复宏汉霖布公告，近日，注射用HLX43(靶向PD-L1抗体－新型DNA拓扑异构酶I抑制剂偶联药物)(“HLX43”)联合汉斯状 (斯鲁利单抗注射液)(“汉斯状”)治疗晚期/转移性实体瘤患者的1b/2期临床研究于中国境内(不包括港澳台地区)完成首例患者给药。目前，全球尚无同类靶向PD-L1的ADC产品获批上市，仅有SGN-PDL1V（来自辉瑞）计划于2025年下半年启动临床III期试验，HLX43为全球第二款也是国内首款进入临床阶段的靶向PD-L1的ADC产品。
此外，4月2日，复宏汉霖宣布HLX04-O治疗湿性年龄相关性黄斑变性（wAMD）中国患者的III期HLX04-O-wAMD-CN研究已成功达到预设的主要研究终点。基于该研究结果，复宏汉霖计划携手亿胜生物在中国递交HLX04-O的新药上市申请（NDA）。HLX04-O有望成为中国首个获批用于眼科相关疾病治疗的贝伐珠单抗制剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.